The dawn of a new era: early minimally invasive removal of intracerebral hemorrhage

Intracerebral hemorrhage (ICH) stands as one of the most daunting challenges in the field of neurosurgery and neurocritical care. The incidence of ICH is 29.9 per 100 000 person-years (95% CI=26.5–33.3), with an increased risk of development in men and Asian population1. The high morbidity, mortality, and the significant socio-economic burden associated with ICH is alarming2–4. The traditional approach to ICH management has largely been conservative, focusing on medical management aimed at mitigating secondary brain injury while the body attempts to resolve the hemorrhage over time5,6. This conservative stance is rooted in historical clinical trial outcomes that have, until now, provided little evidence to support the routine use of surgical intervention in the management of supratentorial ICH. However, the Early Minimally Invasive Removal of Intracerebral Hemorrhage (ENRICH) trial represents a pivotal shift in our approach to treating this devastating condition, offering renewed hope and a potential paradigm shift in patient care. The multicenter, randomized ENRICH trial meticulously explored the efficacy of early minimally invasive surgery (MIS) in conjunction with guideline-based medical management versus medical management alone in 300 patients with ICH. Targeting patients with acute lobar or anterior basal ganglia hemorrhages within a critical volume range, the trial’s design was both innovative and reflective of a deep understanding of the pathophysiology of ICH and the technological advancements in neurosurgery. By incorporating a utility-weighted modified Rankin scale to assess outcomes, the study provided a nuanced view of patient recovery, emphasizing functional outcomes and quality of life—a perspective that aligns well with the priorities of patients and their families. The mean score on the utility-weighted modified Rankin scale at 180 days was 0.458 in the surgery group and 0.374 in the control group7. This improvement in functional outcomes at 180 days post-hemorrhage for patients receiving early MIS the trial highlights the critical importance of timing and the potential benefits of intervening before the secondary effects of ICH can exert their full toll on brain tissue. This improvement was particularly pronounced in patients with lobar hemorrhages, a subgroup that, as the trial progressed, became the exclusive focus of enrollment due to the adaptation rules of the study design7. Additionally, the observed reduction in early mortality (9.3% vs. 18.0%) within the surgical group than the medical management alone group emphasizes the safety and potential life-saving benefits of this approach7. As we dive deeper into the implications of the ENRICH trial, several key points emerge that should guide our future practice and research. Firstly, the trial’s outcomes underscore the necessity of a tailored approach to ICH treatment. The distinction between outcomes in patients with lobar versus basal ganglia hemorrhages speaks to the heterogeneity of ICH presentations and the need for personalized treatment plans. This finding warrants further research to refine our understanding of which patients are most likely to benefit from surgical intervention and at what point in their clinical course. Secondly, the trial’s success hinges not only on the concept of surgical evacuation but also on the minimally invasive techniques employed. Traditional craniotomy, with its associated risks and complications, has given way to more sophisticated approaches that minimize tissue damage and offer a safer passage to the hemorrhage site. The use of technologies like the BrainPath and Myriad devices in the ENRICH trial represents the forefront of neurosurgical innovation, marrying the precision of modern engineering with the art of surgery. The continuous development and refinement of MIS techniques will undoubtedly play a central role in improving outcomes for ICH patients. Lastly, the ENRICH trial’s design and adaptive approach serve as a model for future clinical research in neurosurgery. By allowing for the modification of enrollment criteria based on interim outcomes, the trial ensured that its findings would be both robust and relevant. This methodological rigor and flexibility enhance the applicability of the results to clinical practice, providing a strong foundation upon which to base treatment decisions. However, despite the optimism warranted by the ENRICH trial, we must also recognize the limitations and unanswered questions that remain. The differential outcomes based on hemorrhage location invite further exploration into the pathophysiological mechanisms that may underlie these variations. The trial did not include patients with hematoma volume less than 30 or greater than 80 ml and those with thalamic/intraventricular extension. Also, recruitment of patients with anterior basal ganglia hemorrhages was halted, which limits the applicability of study’s findings. Additionally, long-term follow-up beyond 180 days is necessary to fully understand the sustainability of the benefits observed and the potential long-term complications or outcomes associated with early MIS. Finally, cost-effectiveness analyses and considerations of resource availability will be essential in determining how these interventions can be broadly implemented in diverse healthcare settings. In conclusion, the ENRICH trial marks a significant milestone in our journey to improve outcomes for patients suffering from ICH. By demonstrating the potential benefits of early, minimally invasive surgical intervention, this study provides a beacon of hope and a call to action. It challenges us to rethink our traditional approaches, to embrace innovation in surgical technology, and to pursue a deeper understanding of the complex dynamics at play in ICH. Source of funding None. Author contribution A.A.: conceptualization, project administration, supervision, validation, visualization, writing—original draft and writing—review and editing. A.V.: visualization, writing—original draft and writing—review and editing. N.A.W.: project administration, validation, visualization, writing—original draft and writing—review and editing. P.S.: supervision, validation, writing—review and editing. R.K.S.: supervision, validation, writing—review and editing. D.S.: supervision, validation, writing—review and editing. M.A.: supervision, validation, writing—review and editing. M.N.K.: supervision, validation, writing—review and editing. S.G.: supervision, validation, writing—review and editing. Q.S.Z.: supervision, validation, writing—review and editing. S.R.: supervision, validation, writing—review and editing. Conflicts of interest disclosure The authors declare no conflicts of interest.

Récupéré en direct depuis OpenAlex et désinversé. Les résumés ne sont pas conservés dans cette base de données : les index inversés représentent 8,6 Go des 9,3 Go de texte de la base, et le serveur dispose de 13 Go libres.